Dernières nouvelles
Information non disponible
- Denis-Langlois, May-LinaEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67517may-lina.denis-langlois@crchudequebec.ulaval.ca
1401 18e Rue
G3.382
Québec, QC
Canada G1J 1Z4 - Gontier, ÉmilieEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67529emilie.gontier@chudequebec.caemilie.gontier@crchudequebec.ulaval.ca
1401, 18e rue
G3.457
Québec, QC
Canada G1J 1Z4 - Hébert, YolaineEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67515+1 418-649-5956yolaine.hebert@chudequebec.cayolaine.hebert@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4 - Nadeau, PhilippeEmployéHôpital de l'Enfant-Jésus+1 418-649-0252, poste 67324+1 418-649-5956philippe.nadeau@chudequebec.caphilippe.nadeau@crchudequebec.ulaval.ca
1401, 18e Rue
G2.466
Québec, Québec
Canada G1J 1Z4 - Tremblay, Marie-ClaudeEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67519+1 418-649-5733Marie-Claude.Tremblay@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4 - Tremblay, MichèleEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67518+1 418-649-0252, poste 63115+1 418-649-5956michele.tremblay@chudequebec.camichele.tremblay@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4 - Vallée, LindaEmployéHôpital de l'Enfant-Jésus+1 418-525-4444, poste 67516+1 418-649-5956linda.vallee@chudequebec.calinda.vallee@crchudequebec.ulaval.ca
1401, 18e Rue
G3.382
Québec, Québec
Canada G1J 1Z4
How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists
Article de revueCurr Oncol, 30 (4), 2023.
CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study
Article de revueClin Lymphoma Myeloma Leuk, 23 (3), 2023.
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Article de revueJ Clin Oncol, 40 (28), 2022.
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Article de revueBlood, 140 (21), 2022.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Article de revueBlood, 137 (5), 2021.
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients
Article de revueBiol Blood Marrow Transplant, 25 (8), 2019.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Article de revueN Engl J Med, 379 (10), 2018.
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
Article de revueAnn Oncol, 29 (3), 2018.
Exercise Lowers Plasma Angiopoietin-Like 2 in Men with Post-Acute Coronary Syndrome
Article de revuePLoS One, 11 (10), 2016.
An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT
Article de revueCurr Oncol, 22 (4), 2015.